Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
2024年5月29日 - 9:00PM
Merus to Participate in a Fireside Chat at the Jefferies Global
Healthcare Conference
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company
developing innovative, full-length multispecific antibodies
(Biclonics® and Triclonics®), today announced that Bill Lundberg,
M.D., President, Chief Executive Officer of Merus, will participate
in a fireside chat at the Jefferies Global Healthcare Conference on
Wednesday, June 5, 2024 at 11:00 a.m. ET.
The webcast of the presentation will be contemporaneously
available on the Investors page of the Company's website. The
archived presentation will also be available there for a limited
time after the event.
About MerusMerus is a
clinical-stage oncology company developing innovative full-length
human bispecific and trispecific antibody therapeutics, referred to
as Multiclonics®. Multiclonics® are manufactured using industry
standard processes and have been observed in preclinical and
clinical studies to have several of the same features of
conventional human monoclonal antibodies, such as long half-life
and low immunogenicity. For additional information, please visit
Merus’ website, X and LinkedIn.
Multiclonics®, Biclonics® and Triclonics® are registered
trademarks of Merus N.V.
Merus NV (TG:2GH)
過去 株価チャート
から 8 2024 まで 9 2024
Merus NV (TG:2GH)
過去 株価チャート
から 9 2023 まで 9 2024